Accreditation/
Credit Designation
Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Bristol Myers Squibb, Novartis Pharmaceuticals Corporation, and Taiho Oncology.
Oncology Best Practice™: From Trials to Clinical Practice: Understanding the Latest Evidence for the Treatment of Myelodysplastic Syndromes
Oncology Best Practice™: From Trials to Clinical Practice: Understanding the Latest Evidence for the Treatment of Myelodysplastic Syndromes
In order to request this CME/CE activity for your center, please contact Samantha Zelasko at [email protected]
Start date: April 30, 2021
Overview
The management of myelodysplastic syndrome (MDS) has advanced rapidly in recent years, with new treatment approaches for symptoms and disease control. However, translation of clinical trial data into practice remains a significant challenge, particularly in the community setting, where clinicians may see only sporadic cases of MDS.
The goal of this Oncology Best Practice™ series is to provide up-to-date recommendations for risk stratification and management of MDS to hematology/oncology professionals, as well as treatments on the horizons for these hematologic malignancies. This series of live, virtual meetings will include multiple formats for learning, including data presentations, case presentations, and faculty Q&A.
Benefits of Attending
- Get up-to-date with risk stratification for MDS
- Discuss practical challenges for management of MDS with expert faculty
- Learn about the latest research into emerging treatment options for MDS
- Engage with case scenarios to enhance your knowledge of best practices in MDS management
Acknowledgment of Commercial Support
This activity is supported by educational grants from Bristol Myers Squibb, Novartis Pharmaceuticals Corporation, and Taiho Oncology.
Target Audience
This educational activity is directed toward hematology/oncology physicians, pathologists, oncology nurses, and other health care professionals involved in the treatment of patients with MDS.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Summarize the criteria for MDS diagnosis and methods for risk stratification
- Explain the impact of risk assessment on treatment selection in patients with MDS
- Assess the efficacy and safety profiles for current and emerging agents/combinations in patients with MDS
- Evaluate recent evidence from landmark trials within the context of current treatment paradigms for patients with MDS
Program Chair
McCredie Professor of Medicine
Chief, Section of MDS
Vice Chair, Dept. of Leukemia
University of Texas
MD Anderson Cancer Center
Houston, TX
